Introduction
Knowledge of the sequence of the luteinizing hormone-releasing hormone (LH-RH), < Glu-Hisa Reprint requests to Prof. Dr. K. Folkers. 0340-5087/82/0200-0246/$ 01.00/0
Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 [1] [2] [3] , opened a new field in peptide research of medicinal importance. LH-RH, formed in the hypothalamus, releases the luteinizing hormone (LH), in the pituitary. Also, LH-RH can release the follicle stimulating hormone (FSH). Both LH and FSH are required for ovulation and pregnancy. LH-RH and analogues which are more potent and stable in vivo would be expected to be useful for stimulating ovulation. Inhibitors of LH-RH would be expected to be useful for contraception.
Reviews on structure-activity studies and on clinical evaluation have appeared [4] [5] [6] . We have written this review as a critique of eight years of our research on the design and evolution of inhibitors of ovulation of ever increasing potency. This critique allows the activities of many analogues, in vitro and in vivo, to be compared by the same assays. Also, some very recent new data are included.
For the in vitro assays, only the results for inhibition of LH release are given because, with few exceptions, the inhibition of FSH release approximately parallels the inhibitions of LH release. However, for the more active inhibitors, the inhibition of LH release appears to be slightly more facile than the inhibition of FSH release.
Several discoveries, which now have historical importance, are particularly worthy of emphasis, because they provided the basis for most current studies. Five such events are as follows.
(1) The replacement of Gly 6 in LH-RH by Damino acids [7] , especially D-aromatic amino acids [8, 9] , resulted in agonists of enhanced activity. This modification has also been found to be desirable in the design of inhibitors.
(2) The replacement of -Pro 9 -Gly 10 -NH2 by, for example, -Pro 9 -NHET [10] led to agonists of enhanced potency. Although the incorporation of this C-terminal modification into inhibitor sequences has led to inhibitors in which the in vitro potency was retained, reduced, or enhanced, the antiovulation potency was significantly reduced, in general.
(3) The replacement of Leu 7 by N-Me-Leu in certain agonist sequences has led to retained or enhanced activity [11] . In the design of ovulation inhibitors, this modification has not been useful, probably because D-Phe or D-Trp, rather than D-Ala was in position 6.
(4) The replacement of His 2 or Trp 3 [12, 13] has given inhibitors in vitro. Later work has shown that for potent ovulation inhibitors, substitutions at positions 2 and 3 and incorporation of a D-Phe 2 residue are essential. In early studies on the design of inhibitors of LH-RH, it was assumed that a potent inhibitor in vitro would be an inhibitor of ovulation. The demonstration that [D-Phe 2 , D-Ala 6 ]-LH-RH inhibited spontaneous ovulation in rats at 12 or 24 mg/kg (six divided injections, s.c.), depressed the pre-ovulatory LH-FSH singe and inhibited pregnancy in successfully inseminated recipients, bore out this assumption [14] .
Results and Discussions

Inhibitors having L-amino acids in positions 2 and 3 and allcyl amino acids in position 6 (Table I)
The decapeptide [Leu 2 , Leu 3 ]-LH-RH (1) inhibited the action of LH-RH in vitro, with an analogue to LH-RH ratio of 300,000:1. Although this analogue was of very low potency and was inactive in vivo, it was the challenging basis which led to the current substitutions in both positions 2 and 3.
The replacement of Leu 3 in [Leu 2 , Leu 3 ]-LH-RH by Ser (2) and Asn (3) decreased activity and the replacement of Leu 2 by Thr (4) led to the retention of inhibitory activity in vitro.
The analogue [Leu 2 , Leu 3 , D-Ala 6 ]-LH-RH (5) was up to ten-fold more potent than analogue 1 and demonstrated the desirability of substituting a D-amino acid in position 6 for an antagonist. Structural variation at position 2 gave an order of potency of Phe 2 (7) > Leu 2 (5), Val 2 (6), which demonstrated the desirability of substituting an aromatic amino acid into position 2. The replacement of Leu 3 in analogue 5 by Ala (10) or Val (11) decreased potency. The D-Leu 6 analogues 8 and 9 were of similar potencies to that of analogue 5.
The weak antiovulatory activity at 3 mg observed for analogues 5 and 8 reflects their weak in vitro activity (10 jug [19] .
Therefore, in contrast with studies on LH-RH agonists, the ethylamide modification has not been desirable in the design of inhibitors. 
Inhibitors having D-aromatic amino acids in positions 2 and 6 and substitution in position 3
The incorporation of D-Phe into position 2 and either D-Trp or D-Phe into position 6 has been found to significantly enhance inhibitory potency and has led to analogues which completely inhibit ovulation at 750 ^ug/rat and which inhibit the action of 0.6 ng LH-RH in vitro, at 0.1 ng (analogue to LH-RH ratio 166:1). The data in Table VI show that these analogues inhibit reversibly in vitro with the ease of reversal being structure dependent.
Inhibitors based on changes in positions 1,2, 3 and 6
The analogues of Tables VII to IX show the effect of structural modification of the < Glu residue in position 1 for 1,2,3,6-tetra-substituted analogues.
The Cpc analogue, [Cpc*, D-Phe 2 , Pro 3 , D-Phe 6 ]-LH-RH (66), was as active in vitro as the corresponding <Glu analogue 43. Therefore, the <Glu x residue is not necessary for potent inhibitory activity at least at the pituitary level. Surprisingly, the Cpc analogue did not inhibit ovulation at 750 /ig/rat under our standard assay conditions. The related analogues having acetyl in position 1 (69) and the shortened des 1 (Tables VIII  and IX) . Although the antiovulatory activities of 2,3,6-trisubstituted LH-RH sequences having D-Trp, Pro or N-Me-Leu in position 3 were comparable (Section 7), the substitution of <Glu x by D-<Glu in these sequences resulted in enhancement of potency for the D-Trp 3 analogue and a reduction of potency for the Pro 3 and N-Me-Leu 3 analogues. It is possible that the Pro and N-Me-Leu, but not the D-Trp, in position 3 exists in a trans-cis equilibrium, and that the substitution of D-< Glu adversely affects this equilibrium by altering binding capability and/or transportation. Although such an explanation could also be applied, at least in part, to analogues 66 to 75, other factors, such as enzymatic and transportation effects, also need to be considered.
The analogues 86 to 98 in Table IX show 
Inhibitors based on linear sequences longer than decapeptides
One aspect of our structure-activity studies on the Ac-Pro 1 analogue (87) involved replacing the CH3CO-group, which can be regarded as des-aminoGly, by other amino acid residues. That is, peptide fragments were substituted into position 1 in the [residue 1 , D-Phe 2 , D-Trp 3 , D-Trp 6 ]-LH-RH sequence (Table X) .
The order of antiovulatory potency for some undecapeptide analogues in which residue 1 was varied was <Glu-Pro (99) (100%, 200 ng) > Therefore, in contrast to agonist sequences, position 1 in inhibitors can accomodate at least dipeptide fragments and linear peptides, longer than a decapeptide, now constitute a new class of potent ovulation inhibitors. The presence of the rigid ring of Pro and a "protected" N-terminus may be important.
Miscellaneous analogues
These analogues, shown in Table XI , exhibited low inhibition activities and/or agonist properties. The analogue 110 significantly released LH and FSH at 100 ng at a ratio of LH: FSH greather than that induced by LH-RH.
Irreversible inhibition
The incorporation into peptide sequences of chemically reactive groups capable of reacting with moieties on or in the vicinity of the LH-RH receptor^), represents an alternative design. One analogue, [chlorambucil 1 , Leu 2 , Leu 3 , D-Ala 6 ]-LH-RH (113), has been shown to inhibit the action of LH-RH, in a modified in vitro assay in which the pituitaries were pre-incubated with the analogue (3 to 5 ng) prior to adding LH-RH (0.3 ng) (Table XII) . This protocol was necessary, because the analogue unexpectedly acted as an agonist at dosages of 1 to 100 ng in contrast to [Leu 2 , Leu 3 , D-Ala 6 ]-LH-RH. Multiple treatments were more effective than a single incubation. Unlike [Leu 2 , Leu 3 , D-Ala 6 ]-LH-RH, the chlorambuciU-analogue 113 irreversibly inhibited in vitro. The chlorambucil 1 -analogue did not release TSH or GH indicating that its activities could be specific at the receptor site for LH-RH [28] .
On the correlation of LH-RH inhibition assays and antiovulatory assays
In general, only a partial correlation exists between the results of in vitro and antiovulation assays. All analogues which inhibit ovulation at 750 ^g/rat or less strongly inhibit in vitro at an analogue to LH-RH ratio of 166:1. However, many exceptions are now evident. Not all analogues active at 166:1 or less in vitro inhibit ovulation at 750/zg/rat or at substantially increased dosages.
Comparative studies have given the following results [29] (Table XIII) .
(1) Inhibitors having comparable potency in vitro can display a range of antiovulatory activities. 
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A LH ng/ml medium ± SEM (p Propylene glycol control. Antiovulatory activity: 1.5 X 2 mg/rat, 5/6 rats ovulated.
(2) The above two analogues were essentially equipotent in inhibiting LH-RH in adult male chimpanzees at a ratio of 333:1 and in adult male rats at 100:1, in contrast with their relative antiovulatory activities. However, at a ratio, of 30:1 in rats, only the Ac-Pro 1 analogue inhibited. fig, inactive at 750 fig, 200 fig, 200 fig and  200 fig, respectively. (4) Ovulation inhibitors, active at 200/zg/rat, also inhibited LH-RH in adult male chimpanzees at a ratio of analogue to LH-RH of 333:1.
Since the Cpc-analogues inhibit LH-RH in vitro and in vivo, their lack of activity in the antiovulation assay cannot readily be explained in terms of enzymatic inactivation or differences in metabolism. had comparable activities in vitro, but only analogue 39 inhibited ovulation at 750 yug/rat. Surprisingly, analogue 78 had significant agonist activity at 100 /ig in vitro, which presumably masked its inhibitory activity. The results on these L-Trp 3 analogues, i.e., inhibitors based on changes in positions 2 and 6, or in positions 1,2, and 6, emphasize the importance of designing inhibitors having suitable substitution in position 3.
Table XIH. Comparative assays of LH-RH inhibitors for inhibition of LH-RH and inhibition of ovulation.
Inhibition of LH-
A priori, it seems reasonable to conclude that LH-RH inhibitors inhibit ovulation in rats by acting on the pituitary and inhibiting the LH-FSH preovulatory surge on proestrus. The analogues are most effective when administered near the LH-FSH surge and the most active ovulation inhibitors very effectively inhibit both the LH and FSH responses of LH-RH in vitro and in vivo, although the reverse is not always true.
Small hypothalamic hypophysiotropic peptides act at multiple anatomic sites and exhibit multiple functional activities. Although there is indirect evidence that LH-RH inhibitors could act at additional sites, for example, the ovary, direct evidence is not yet available.
Inhibition of ovulation in rhesus monkeys
One 
Inhibition by a minipump (Alza Corp.)
The infusion of [D-Phe 2 , Pro 3 , D-Trp 6 ]-LH-RH in propylene glycol at a rate of 375 //g/day for 4 days from a s.c. implanted minipump completely inhibited ovulation in cycling female rats and decreased serum LH levels in castrated male rats. The corresponding Leu 3 analogue was not effective. The infusion of LH-RH and the super agonist des -Gly 10 [D-Ala 6 ]-LH-RH ethylamide at 375 and 6 ^g/day, respectively, for 4 days completely blocked uterine implantation sites of mated rats. In contrast, the Pro 3 and Leu 3 inhibitors did not block the uterine implantation sites indicating a difference in mechanism of contraception for agonists and inhibitors of LHRH [30] .
Perspectives
With the currently available analogues, the proposal that LH-RH inhibitors can act ac ovulation inhibitors has been proven at least in rats and monkeys.
In the design of these inhibitors, it has been found that certain structure-activity relationships for LH-RH agonists can be carried over the design of inhibitors. The most potent ovulation inhibitors have substitutions in positions 1, 2, 3 and 6, i.e. in four out of ten positions. Structural modification in, for example, positions 1, 2 and 3, could influence the conformation of the molecule to such an extent that the optimum substitution for other parts of the molecule could be different for agonists and inhibitors. This would necessitate the synthesis of LH-RH analogues with five or more changes in the molecule.
The discovery of the highly potent undecapeptide analogue, [(<Glu-Pro)i, D-Phe 2 , D-Trp 3 , D-Trp 6 ]-LH-RH, has opened a new category of peptides longer than decapeptides. Analogues in this category could also be designed which (1) have different degress of lipophilicity (c/. the high antiovulatory activity of the N-Ac-Thr-analogue 97), or (2) "prodrug" characteristics.
With the ever growing synthesis of specially designed sequences and the expansion of primate studies, the design of inhibitors or LH-RH as ovulation inhibitors is one of great promise.
Experimental
Synthesis of analogues of LH-RH
Amino acid derivatives. -Intermediates were purchased from Peninsula Laboratories, San Carlos, California 94070, which markets products made by the Protein Research Foundation, Japan.
Protecting groups
N a -protection. -The butyloxycarbonyl group (Boc-) was used for all amino acid derivatives with the exception of Arg, when the more soluble Aocprotected derivative was used. The <Glu-residue was incorporated as the more soluble Z-<Glu-OH derivative.
Side chain protection. -The following protecting groups were used: Tos for His and Arg; BZ1 for Ser, Thr and Gly; o-Br-Z for Zyr; o-Cl-Z for Lys.
Active ester derivatives. -Gin and Asn residues were incorporated as their p-nitrophenyl esters.
Resins. -As most of these LH-RH analogues are peptide amides, the benzhydrylamine hydrochloride resin (1% cross-linked) as market by Beckman Instruments, Palo Alto, California 94304, was used. When analogues with other C-terminals are desired, the Merrifield chloromethylated resin was used. The PAM-resin which has a more acid stable peptide to resin covalent bond attachment has also been used.
Solid phase synthesis
Attachment of first amino acid to the resin. -The benzhydrylamine resin hydrochloride was neutralized with 25% triethylamine (redistilled from NaOH pellets and ninhydrin) in methylene chloride. The first amino acid derivative was attached by the DCC method until the ninhydrin color test was negative.
The Merrifield resin was stirred overnight with an equivalent amount of the lithium salt of the protected amino acid in 6-8 ml DMF per gram resin at 50 °C.
Deprotection. -The protecting group of the anitrogen (Boc, Aoc) was removed by stirring the protected peptide-resin with 50% (w/v) trifluoroacetic acid (TFA) in methylene chloride containing 0.1% (w/v) indole for 30 min after the resin had been pre washed with this reagent.
Neutralization. -The trifluoroacetate salt of the peptide-resin from the deprotection step was neutralized with 10% (v/v) triethylamine (redistilled from ninhydrin and NaOH pellets) in methylene chloride for 10 min after 2 pre washes with the neutralizing reagent.
Coupling. -In all dicyclohexylcarbodiimide (DCC)-mediated coupling reactions, 2-to 3-equivalents of a solution of 10% (v/v) DCC (redistilled) in methylene chloride was used. Generally, a double coupling procedure was performed to insure complete coupling of amino functions on the resin. A 2-to 3-fold excess of the amino acid derivative was used.
Monitoring coupling reactions. -The ninhydrin color test of Kaiser et al. was used, in duplicate, and with a blank reference for comparison of color.
Avoiding incorrect sequences. -The free residual amino groups (after several incomplete couplings) were acylated with 3% (w/v) nitrophthalic anhydride in pyridine.
Automated peptide synthesis. -All reactions were under an atmosphere of pre-purified grade nitrogen. Liquids were removed from the teflon reaction vessel containing the resin (1 to 10 g) by means of a positive pressure of N2, through the syntered disc at the base of the reaction vessel. An adjustable drain time dial controls the time of operation. Five mixing timers allows the instrument to select suitable times for the washing, deprotection, neutralization, and coupling steps. The amino acid delivery control sets the time necessary for delivery of the CH2CI2, CH2CI2-DMF, or DMF solutions of the amino acid derivatives. Reagents and wash solvents were contained in reservoirs and metered by N2-pressure to two metering columns. Metering column B was for TFA and one CH2CI2 wash reservoir. All other reagents and solvents were metered into metering column A. The volumes of these solutions were controlled by photo-electric sensors.
Programs for synthesis. -The peptide synthesizer operates, when in the "Automated Mode", by reading instructions from a punched mylar tape loop. A loop may contain either complete programs for commonly used coupling procedures or the single steps like deprotection, neutralization, various couplings, and washing, as different programs. The latter loop allows a combination of various steps, individually.
